NASDAQ:PTLA - Portola Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $33.05 -0.24 (-0.72 %) (As of 03/19/2019 04:41 AM ET)Previous Close$33.29Today's Range$32.80 - $33.7952-Week Range$14.81 - $45.60Volume618,466 shsAverage Volume1.64 million shsMarket Capitalization$2.21 billionP/E Ratio-6.60Dividend YieldN/ABeta2.37 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Portola Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness. It is also advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. In addition, the company is developing PRT2761, a Syk inhibitor candidate for the treatment for allergic conjunctivitis. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Bayer Pharma, AG; Janssen Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Dermavant Sciences GmbH; and Ora, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California. Receive PTLA News and Ratings via Email Sign-up to receive the latest news and ratings for PTLA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTLA Previous Symbol CUSIPN/A CIK1269021 Webwww.portola.com Phone650-246-7000Debt Debt-to-Equity Ratio2.25 Current Ratio5.12 Quick Ratio5.01Price-To-Earnings Trailing P/E Ratio-6.60 Forward P/E Ratio-8.54 P/E GrowthN/A Sales & Book Value Annual Sales$40.13 million Price / Sales55.03 Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book24.30Profitability EPS (Most Recent Fiscal Year)($5.01) Net Income$-350,220,000.00 Net Margins-872.72% Return on Equity-167.94% Return on Assets-71.76%Miscellaneous EmployeesN/A Outstanding Shares66,821,000Market Cap$2.21 billion Next Earnings Date5/8/2019 (Estimated) OptionableOptionable Portola Pharmaceuticals (NASDAQ:PTLA) Frequently Asked Questions What is Portola Pharmaceuticals' stock symbol? Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA." How were Portola Pharmaceuticals' earnings last quarter? Portola Pharmaceuticals Inc (NASDAQ:PTLA) released its quarterly earnings results on Friday, March, 1st. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($1.11) by $0.07. The biopharmaceutical company had revenue of $15.30 million for the quarter, compared to analyst estimates of $10.53 million. Portola Pharmaceuticals had a negative return on equity of 167.94% and a negative net margin of 872.72%. The firm's revenue was up 56.1% on a year-over-year basis. During the same period in the previous year, the company posted ($1.41) earnings per share. View Portola Pharmaceuticals' Earnings History. When is Portola Pharmaceuticals' next earnings date? Portola Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for Portola Pharmaceuticals. What price target have analysts set for PTLA? 7 Wall Street analysts have issued 12 month price targets for Portola Pharmaceuticals' shares. Their predictions range from $30.00 to $50.00. On average, they expect Portola Pharmaceuticals' stock price to reach $36.80 in the next year. This suggests a possible upside of 11.3% from the stock's current price. View Analyst Price Targets for Portola Pharmaceuticals. What is the consensus analysts' recommendation for Portola Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Portola Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Portola Pharmaceuticals. What are Wall Street analysts saying about Portola Pharmaceuticals stock? Here are some recent quotes from research analysts about Portola Pharmaceuticals stock: 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (2/21/2019) 2. Cowen Inc analysts commented, "Rhythm reported 2Q18 financial results yesterday and we spoke w/ mgmt for an update. As a reminder, the company completed enrollment of both setmelanotide Phase 3 trials in POMC and LepR Deficiency patients in Jun 2018. Mgmt reiterated guidance for results from these trials in 3Q19. We expect positive outcomes based on Phase 2 data. Encouraging long-term Phase 2 data in Bardet-Biedl (BBS) and initial Phase 2 data in Alstrom, POMC Heterozygous, and POMC Epigenetic were announced earlier this year and mgmt reiterated plans to start a single Phase 3 trial w/ both Bardet-Biedl and Alstrom patients in 2H18. Demonstration of consistent impact on appetite and weight across several genetic obesity diseases in 2Q18 has increased our conviction. BUY." (8/9/2018) Has Portola Pharmaceuticals been receiving favorable news coverage? Headlines about PTLA stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Portola Pharmaceuticals earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. Are investors shorting Portola Pharmaceuticals? Portola Pharmaceuticals saw a drop in short interest in the month of February. As of February 28th, there was short interest totalling 15,236,315 shares, a drop of 9.4% from the February 15th total of 16,823,205 shares. Based on an average daily trading volume, of 1,315,723 shares, the days-to-cover ratio is presently 11.6 days. Currently, 23.9% of the shares of the stock are short sold. View Portola Pharmaceuticals' Current Options Chain. Who are some of Portola Pharmaceuticals' key competitors? Some companies that are related to Portola Pharmaceuticals include H. Lundbeck A/S- (HLUYY), Molina Healthcare (MOH), bluebird bio (BLUE), Davita (DVA), Guardant Health (GH), Bausch Health Companies (BHC), Fisher & Paykel Healthcare (FPH), Beigene (BGNE), Jazz Pharmaceuticals (JAZZ), West Pharmaceutical Services (WST), Neurocrine Biosciences (NBIX), SAGE Therapeutics (SAGE), NMC HEALTH PLC/ADR (NMHLY), Exelixis (EXEL) and WILLIAM DEMANT/ADR (WILYY). What other stocks do shareholders of Portola Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Portola Pharmaceuticals investors own include Novavax (NVAX), Exelixis (EXEL), NVIDIA (NVDA), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Celgene (CELG), Micron Technology (MU), TG Therapeutics (TGTX) and Progenics Pharmaceuticals (PGNX). Who are Portola Pharmaceuticals' key executives? Portola Pharmaceuticals' management team includes the folowing people: Ms. Mardi C. Dier, Exec. VP, Chief Bus. Officer & CFO (Age 55)Dr. John T. Curnutte, Exec. VP and Head of R&D (Age 67)Mr. Tao Fu, Consultant (Age 47)Mr. J. Scott Garland MBA, Pres & CEO (Age 50)Cara Miller, VP of Investor Relations and Corp. Communications Who are Portola Pharmaceuticals' major shareholders? Portola Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.02%), FMR LLC (1.52%), Brandywine Global Investment Management LLC (1.26%), Sectoral Asset Management Inc (1.24%), Northern Trust Corp (1.21%) and Geode Capital Management LLC (1.10%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Henry Ward Wolff, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals. Which major investors are selling Portola Pharmaceuticals stock? PTLA stock was sold by a variety of institutional investors in the last quarter, including Kornitzer Capital Management Inc. KS, FMR LLC, Bank of New York Mellon Corp, Asymmetry Capital Management L.P., Oppenheimer & Co. Inc., Hudson Bay Capital Management LP, Northern Trust Corp and Harvey Capital Management Inc.. Company insiders that have sold Portola Pharmaceuticals company stock in the last year include Charles J Homcy and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals. Which major investors are buying Portola Pharmaceuticals stock? PTLA stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Peregrine Capital Management LLC, Tamarack Advisers LP, Elk Creek Partners LLC, Foresite Capital Management IV LLC, Macquarie Group Ltd., Tocqueville Asset Management L.P. and Empire Life Investments Inc.. View Insider Buying and Selling for Portola Pharmaceuticals. How do I buy shares of Portola Pharmaceuticals? Shares of PTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Portola Pharmaceuticals' stock price today? One share of PTLA stock can currently be purchased for approximately $33.05. How big of a company is Portola Pharmaceuticals? Portola Pharmaceuticals has a market capitalization of $2.21 billion and generates $40.13 million in revenue each year. The biopharmaceutical company earns $-350,220,000.00 in net income (profit) each year or ($5.01) on an earnings per share basis. What is Portola Pharmaceuticals' official website? The official website for Portola Pharmaceuticals is http://www.portola.com. How can I contact Portola Pharmaceuticals? Portola Pharmaceuticals' mailing address is 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-246-7000 or via email at [email protected] MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 427 (Vote Outperform)Underperform Votes: 271 (Vote Underperform)Total Votes: 698MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe PTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTLA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What causes a recession?